About
Cancer, drug resistance
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (28)
View allTotal Trials
28
As Lead Sponsor
27
As Collaborator
1
Total Enrollment
5,897
By Phase
PHASE1: 15PHASE1/PHASE2: 1PHASE2: 6PHASE3: 6
By Status
COMPLETED: 17TERMINATED: 6RECRUITING: 3WITHDRAWN: 1UNKNOWN: 1
Clinical Trials Pipeline28 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06816992Lead Sponsor
ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
PHASE1Recruiting
76 participants
Started: Feb 27, 2025 · Completed: May 31, 2027
NCT06012721Lead Sponsor
Effect of Food on the Pharmacokinetics of ORIC-114
PHASE1Completed
32 participants
Started: Sep 11, 2023 · Completed: Nov 23, 2023
NCT05413421Lead Sponsor
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
PHASE1Recruiting
250 participants
Started: Jun 1, 2022 · Completed: Sep 30, 2026
NCT05315700Lead Sponsor
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
PHASE1/PHASE2Recruiting
350 participants
Started: Mar 10, 2022 · Completed: Sep 30, 2027
NCT05227144Lead Sponsor
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
PHASE1Completed
31 participants
Started: Jan 6, 2022 · Completed: Mar 3, 2025
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...